Alemtuzumab

Alemtuzumab Reactions 1680, p22 - 2 Dec 2017 Drug eruption and lymphopenia: case report A 32-year-old woman developed drug eruption and lymphopenia during treatment with alemtuzumab [route and dosage not sated]. The woman, who had a history of multiple sclerosis, started receiving treatment with alemtuzumab for three days as per the protocol. After 10 days of initiation of alemtuzumab, she experienced a widespread rash. Laboratory tests showed elevated CRP (67 mg/L) and lymphopenia (lymphocytes 0.2 × 10 /L) which is an expected adverse effect of alemtuzumab. A diagnosis of a drug eruption secondary to alemtuzumab was made. The authors considered drug eruption to be serious. The woman started receiving treatment with steroids and prednisolone. She responded well to the treatment. She recovered completely, and 12 months later, she received different treatment. The treatment with alemtuzumab was restarted. She again developed skin erythema on her forearms and thighs, which resolved immediately. Author comment: "[T]his case of a severe blistering drug eruption secondary to alemtuzumab in a patient who also had a successful re-exposure, is the first reported." Ngu S, et al. A case of severe drug reaction secondary to alemtuzumab with successful re-exposure. Clinical and Experimental Dermatology 42: 925-926, No. 8, Dec 2017. Available from: URL: http://doi.org/10.1111/ced.13230 - United Kingdom 803284975 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Alemtuzumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/alemtuzumab-0i0Vll6tvF
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38953-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p22 - 2 Dec 2017 Drug eruption and lymphopenia: case report A 32-year-old woman developed drug eruption and lymphopenia during treatment with alemtuzumab [route and dosage not sated]. The woman, who had a history of multiple sclerosis, started receiving treatment with alemtuzumab for three days as per the protocol. After 10 days of initiation of alemtuzumab, she experienced a widespread rash. Laboratory tests showed elevated CRP (67 mg/L) and lymphopenia (lymphocytes 0.2 × 10 /L) which is an expected adverse effect of alemtuzumab. A diagnosis of a drug eruption secondary to alemtuzumab was made. The authors considered drug eruption to be serious. The woman started receiving treatment with steroids and prednisolone. She responded well to the treatment. She recovered completely, and 12 months later, she received different treatment. The treatment with alemtuzumab was restarted. She again developed skin erythema on her forearms and thighs, which resolved immediately. Author comment: "[T]his case of a severe blistering drug eruption secondary to alemtuzumab in a patient who also had a successful re-exposure, is the first reported." Ngu S, et al. A case of severe drug reaction secondary to alemtuzumab with successful re-exposure. Clinical and Experimental Dermatology 42: 925-926, No. 8, Dec 2017. Available from: URL: http://doi.org/10.1111/ced.13230 - United Kingdom 803284975 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off